Abby Hardy, Author at BioTuesdays

Markets

SVB Leerink starts Aclaris Therapeutics at OP; PT $13

SVB Leerink initiated coverage of Aclaris Therapeutics (NASDAQ:ACRS) with an “outperform” rating and $13 price target. The stock closed at $6.34 on May 3.

May 6, 2019

Developments

LogicBio’s methylmalonic acidemia candidate gets FDA orphan drug designation

LogicBio Therapeutics’ (NASDAQ:LOGC) investigational pediatric genome editing therapy, LB-001, received FDA orphan drug designation for the treatment of methylmalonic acidemia (MMA). MMA, a rare disease caused by...

April 30, 2019

Developments

MyoKardia’s positive Phase 2 results published in Annals of Internal Medicine

MyoKardia’s (NASDAQ:MYOK) positive Phase 2 trial results of mavacamten for the treatment of obstructive hypertrophic cardiomyopathy (HCM) were recently published in the peer-reviewed journal, Annals of Internal Medicine...

April 30, 2019

Developments

Titan Pharma receives positive EU CHMP opinion for Probuphine (“Sixmo”)

Titan Pharmaceuticals (NASDAQ:TTNP) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for marketing authorization of Sixmo, the brand name for...

April 29, 2019

Developments

Titan Pharma’s Probuphine implant to treat OUD continues to gain national media attention

Channel 8’s Daytime aired nationally an interview with two senior executives of Titan Pharmaceuticals (NASDAQ:TTNP) – Dane Hallberg, EVP and chief commercial officer, and Dr. Kate DeVarney, EVP and chief scientific...

April 26, 2019

Developments

Researchers develop potentially safer CAR-T treatment

Researchers at the University of Southern California’s (USC) Norris Comprehensive Cancer Center have designed a new type of CAR-T treatment that reduces the risk of cytokine release syndrome (CRS), a dangerous immune...

April 23, 2019

Developments

Catasys in OnTrak pact with Optima Health in Virginia

Catasys (NASDAQ:CATS) entered into an agreement with Optima Health to provide its OnTrak solution to eligible commercial members in Virginia, with a launch expected in the second quarter of 2019. Catasys applies...

April 23, 2019

Developments

Molecular Templates IND for HER2-targeted therapy accepted by FDA 

Molecular Templates (NASDAQ:MTEM) IND application for MT-5111, an engineered toxin body targeting HER2, has been accepted by the FDA. MT-5111’s single chain variable fragment and Shiga-like toxin-A subunit respectively...

April 22, 2019

Markets

Stifel starts Principia Biopharma at buy; PT $45

Stifel initiated coverage of Principia Biopharma (NASDAQ:PRNB) with a “buy” rating and $45 price target. The stock closed at $27.81 on April 15.

April 16, 2019

Developments

Albireo Pharma presents positive Phase 2 data for pediatric cholestasis candidate

Albireo Pharma (NASDAQ:ALBO) presented positive Phase 2 data for its drug candidate, A4250, at The International Liver Congress 2019. A4250 is being developed to treat rare pediatric cholestatic liver diseases, where...

April 16, 2019

Author - Abby Hardy

SVB Leerink starts Aclaris Therapeutics at OP; PT $13

LogicBio’s methylmalonic acidemia candidate gets FDA orphan drug designation

MyoKardia’s positive Phase 2 results published in Annals of Internal Medicine

Titan Pharma receives positive EU CHMP opinion for Probuphine (“Sixmo”)

Titan Pharma’s Probuphine implant to treat OUD continues to gain national media attention

Researchers develop potentially safer CAR-T treatment

Catasys in OnTrak pact with Optima Health in Virginia

Molecular Templates IND for HER2-targeted therapy accepted by FDA

Stifel starts Principia Biopharma at buy; PT $45

Albireo Pharma presents positive Phase 2 data for pediatric cholestasis candidate

Subscribe